Lead Product(s) : Cytomegalovirus Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Fernanda P Silveira
Deal Size : Inapplicable
Deal Type : Inapplicable
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Details : Cytomegalovirus Immune Globulin is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 06, 2025
Lead Product(s) : Cytomegalovirus Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Fernanda P Silveira
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Cefiderocol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Monaldi Hospital | Rutgers Robert Wood Johnson Medical School | Pisa University Hospital | Assaf-Harofeh Medical Center | Sheba Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : The Chaim Sheba Medical Center | Rabin Medical Center | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Kedrion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study of KEDRAB® (Rabies Immune Globulin [Human]) conducted in children was the first and only pediatric study for any HRIG available in U.S. The study met its primary objective, which was to confirm the safety of KEDRAB in the pediatric population.
Product Name : Kedrab
Product Type : Vaccine
Upfront Cash : Inapplicable
August 19, 2020
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Kedrion
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oseltamivir Versus Paracetamol for Influenza-like Illness During the Influenza Season
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2018
Lead Product(s) : Oseltamivir Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 14, 2018
Lead Product(s) : Piperacillin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Rabin Medical Center | University of Modena and Reggio Emilia | Tel Aviv Medical Center | Meir Medical Center | Soroka University Medical Center | The Chaim Sheba Medical Center | McGill University Health Centre Research Institute | Jewish General Hospita
Deal Size : Inapplicable
Deal Type : Inapplicable